Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Filsuvez

    - PMLiVE

    Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC

    Almost 1,700 people are diagnosed with bladder cancer in Scotland annually

    - PMLiVE

    Chiesi report highlights incorrect inhaler use among UK asthma patients

    The long-term lung condition affects around 7.2 million people in the UK

    - PMLiVE

    Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC

    The rare muscle-wasting disorder affects approximately 2,500 males in the UK at any one time

    - PMLiVE

    Chiesi Group invests €400m to establish biotech centre of excellence in Italy

    The facility is dedicated to developing and producing monoclonal antibodies, enzymes and other proteins

    - PMLiVE

    Chiesi’s rare disorder therapies approved by SMC for Fabry disease and epidermolysis bullosa

    Rare diseases currently affect around 436,000 people living in Scotland

    - PMLiVE

    Bristol Myers Squibb’s Opdualag approved by SMC for advanced melanoma

    The fifth-most common cancer in the UK affects more than 1,200 people in Scotland every year

    - PMLiVE

    Novartis’ Consentyx granted approval by SMC to treat hidradenitis suppurativa

    The drug is available in Scotland on the NHS to treat the chronic inflammatory condition

    - PMLiVE

    Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

    More than 133,520 people in Scotland are affected by the inflammatory condition

    - PMLiVE

    NICE recommends Chiesi’s alpha-mannosidosis enzyme replacement therapy

    Alpha-mannosidosis, an extremely rare inherited condition characterised by a broad range of impairments, affects approximately 25 people in England

    - PMLiVE

    NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

    Affecting approximately 1,150 people in England, Fabry disease is a rare genetic disease that can lead to progressive damage to vital organs

    - PMLiVE

    NICE recommends Amryt’s Filsuvez treatment for epidermolysis bullosa

    Approximately 670 people in England are expected to benefit from the skin-wound-healing treatment

    - PMLiVE

    SMC enables access to Kyowa Kirin’s Crysvita for adults with rare genetic disease

    XLH is a life-long genetic disease that causes abnormalities in the bones, muscles and joints

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links